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Attention deficit hyperactivity disorder (ADHD)
is a complex condition with environmental and
genetic etiologies. Up to this point, research has
identified genetic associations with candidate
genes from known biological pathways. In order
to identify novel ADHD susceptibility genes,
600,000 SNPs were genotyped in 958 ADHD pro-
band-parent trios. After applying data cleaning
procedures we examined 429,981 autosomal SNPs
in 909 family trios. We generated six quantitative
phenotypes from 18 ADHD symptoms to be used in
genome-wide association analyses. With the PBAT
screening algorithm, we identified 2 SNPs,
rs6565113 and rs552655 that met the criteria for
significance within a specified phenotype. These
SNPs are located in intronic regions of genes
CDH13 and GFOD1, respectively. CDH13 has been
implicated previously in substance use disorders.
We also evaluated the association of SNPs from a
list of 37 ADHD candidate genes that was specified
a priori. These findings, along with association P-
values with a magnitude less than 105, are
discussed in this manuscript. Seventeen of these
candidate genes had association P-values lower
then 0.01: SLC6A1, SLC9A9, HES1, ADRB2, HTR1E,
DDC, ADRA1A, DBH, DRD2, BDNF, TPH2, HTR2A,
SLC6A2, PER1, CHRNA4, SNAP25, and COMT.
Among the candidate genes, SLC9A9 had the
strongest overall associations with 58 association
test P-values lower than 0.01 and multiple associa-
tion P-values at a magnitude of 105 in this gene. In
sum, these findings identify novel genetic associa-
tions at viable ADHD candidate genes and provide
confirmatory evidence for associations at previous
candidate genes. Replication of these results is
necessary in order to confirm the proposed genetic
variants for ADHD.  2008 Wiley-Liss, Inc.
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INTRODUCTION
Attention deficit hyperactivity disorder (ADHD) is a complex
disorder characterized by developmentally inappropriate
levels of inattention, hyperactivity, and impulsivity that has
an onset in childhood. Despite a heritability estimate that
averages around 76% [Faraone, 2004; Faraone et al., 2005],
identifying genes associated with ADHD has been difficult.
Using the suspected pathophysiology of the disease as a
starting point, some genetic variants have been implicated
through candidate gene studies and subsequent meta-analy-
ses. These include HTR1B, DRD4, SLC6A3/DAT1, SNAP25,
DRD5, and DBH [Brookes et al., 2006]. However, apart from
some genetic linkage analyses that have identified a few
potential disease susceptibility loci, as of yet no hypothesis-free
genetic mapping studies have been performed for ADHD.
Recent advances in high throughput genotyping technologies
have facilitated the cost-effective genotyping of hundreds of
thousands of DNA markers. Consequently, genome-wide
association studies (GWAS) have become a reality. GWAS
hold huge promise for identifying genetic variants that may not
be obvious a priori biological candidates. GWAS have already
been successful in identifying variants associated with many
complex diseases including obesity, age-related macular
degeneration, Type I and Type II diabetes, Crohn’s disease,
prostate cancer, and celiac disease [Herbert et al., 2006; Rioux
et al., 2007; Saxena et al., 2007; Yeager et al., 2007; Zanke et al.,
2007; Hunt et al., 2008].
The Genetics Analysis Information Network (GAIN) is a public-
private partnership between the NIH and the private sector with
the goal of promoting GWAS for various complex diseases
(http://www.fnih.org/GAIN2/home_new. shtml). Nine hundred
fifty-eight ADHD-parent trios from the International Multicenter
ADHD Genetics Project (IMAGE) were genotyped on a 600K SNP
GWAS as part of the GAIN initiative. We recently reported the
initial findings of the IMAGE GWAS sample using a DSM-IV
diagnosis of ADHD combined type in a family based association
analysis [Neale et al., 2008a]. These findings showed no genome-
wide significant associations but found several promising candi-
dates with P-values<105.
Using DSM-IV ADHD combined type diagnoses, as a
primary phenotype is an obvious first choice for association
analyses, primarily because it is the most severe and common
ADHD subtype and is known to have a relatively high sibling
risk ratio of around 5–10 [Chen et al., 2008]. Despite these
advantages, there is also value in using quantitative measures
of specific aspects of ADHD as the primary phenotypes in
GWAS analyses. Although not commonly used, there is
compelling evidence that the use of quantitative measure-
ments of ADHD is ideal for genetic association studies of
ADHD, as mounting evidence suggests that ADHD is a
disorder on the extreme end of a continuum observed in the
population. Twin studies have found high heritability esti-
mates for ADHD when a quantitative measurement of ADHD
symptoms is used to measure the dimensionality of the
disorder [Edelbrock et al., 1986; Biederman et al., 1993; Chen
et al., 1994; Boyle et al., 1997; Sherman et al., 1997; Faraone
et al., 2005]. Due to their high heritability, the use of such
quantitative ratings generated from the number and severity
of the 18 ADHD symptoms described in the DSM-IV are good
quantitative measures to use in genetic association analyses.
Since the presence of these symptoms is necessary to diagnose
the disorder they are often recorded in other samples, making
replication efforts easy. Using ADHD symptoms also allows for
the analysis of inattentive and hyperactive-impulsive compo-
nents in combined type individuals, separately. In this manu-
script we generated three basic quantitative traits and three
statistically derived quantitative measures from the ADHD
symptoms and then used them as the phenotypes of interest in
GWAS analyses. The statistically derived phenotypes use a
methodology that Lasky-Su et al. [2007, 2008] implemented
previously in the IMAGE sample to identify and replicate an
association with DRD4.
METHODS
Subjects
Families were collected by the International Multicenter
ADHD Genetics (IMAGE) project. Families were identified
through ADHD probands aged 5–17 attending outpatient
clinics at the data collection sites in Europe and Israel. A total
of 958 affected proband-parent trios were initially selected for
the GWAS scan. Family members were Caucasians of Euro-
pean origin from seven countries around Europe including
Belgium, Germany, Ireland, The Netherlands, Spain, Switzer-
land, and The United Kingdom, as well as Israel. Of these, 936
probands were initially ascertained as having DSM-IV
combined type ADHD. Twenty-two probands who did not meet
combined subtype ADHD diagnosis were included because
they either met the criteria for the inattentive or hyperactive
subtypes, or they missed the DSM-IV combined type diagnosis
by a single item. Exclusion criteria were autism, epilepsy,
IQ< 70, brain disorders and any genetic or medical disorder
associated with externalizing behaviors that might mimic
ADHD.
Clinical Measures
Prior to entry into the study, all probands underwent clinical
evaluations by a pediatrician or child psychiatrist and both
existing and new patients were included in the study. Patients
had to meet clinical criteria for ADHD-combined type before
being enrolled in the study. Wherever possible, families
withdrew stimulant medication for 1 week prior to research
assessments to allow for more accurate ascertainment of the
current level of ADHD symptoms and behaviors. Alternatively
we ensured as far as possible that ratings were based on
medication free periods. Probands were excluded from the
study if the last medication free period was more than 2 years
ago.
Parental account of childhood symptom (PACS). PACS
is a semi-structured, standardized, investigator-based inter-
view developed as an instrument to provide an objective
measure of child behavior [Taylor et al., 1986a,b]. A trained
interviewer administers PACS with parents, who are asked for
detailed descriptions of the child’s typical behavior in a range of
specified situations. Such situations are defined either by
external events (e.g., watching television, reading a book or
comic, playing alone, playing with friends, going to bed,
traveling) or by behaviors shown (e.g., crying, worried talk,
tempers, fighting with siblings). Interviewers then make their
own ratings on the basis of a formal training and written
definitions of the behaviors to be rated, on a 4-point scale of
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severity and frequency in the previous week and previous year.
Inter-rater reliability is high with product-moment correla-
tions for pairs of interviewers ranging from 0.79 to 0.96. The
Hyperactivity subscale is made up of attention span (time
spent on a single activity, rated separately for four different
kinds of activity), restlessness (moving about during the same
activities), fidgetiness (movements of parts of the body during
the same activities), and activity level (rated for structured
situations such as mealtimes and car journeys), with other
subscales covering defiant, emotional and other comorbid
disorders including autistic spectrum disorders.
Rating scales. Rating scales used to quantify ADHD
symptoms included the Long Version of Conners’ Parent
Rating Scale (CPRS-R:L), Long Version of Conners’ Teacher
Rating Scale (CTRS-R:L) [Conners, 1996], parent version of the
Strengths and Difficulties Questionnaires (SDQ) and teacher
version of SDQ. In order to exclude autism spectrum disorders
that might confound the analysis of ADHD, both probands and
siblings were screened using the Social Communication
Questionnaire in conjunction with the pro-social scale from
the SDQ. Individuals falling above these thresholds were
further evaluated using the autism spectrum disorder section
of the PACS interview.
DSM-IV diagnoses. All raw data was centralized and
stored on a secure database at the MRC Social Genetic
Developmental Psychiatry research center in London. A
standardized algorithm was applied to PACS to derive each
of the 18 DSM-IV ADHD items, providing operational
definitions for each behavioral symptom. These were combined
with items that scored 2 or 3 from the teacher rated Conners’
ADHD subscale, to generate the total number of items from the
DSM-IV symptom checklist. Situational pervasiveness was
defined as some symptoms occurring within two or more
different situations from the PACS interview, as well as the
presence of one or more symptoms scoring 2 or more from the
ADHD subscale of the teacher rated Conners’.
Quantitative Trait Information Used in the Analyses
Six quantitative traits were generated for use in the
association analyses, three from the CPRS-R:L and three from
the PACS. Both the CPRS-R:L and the PACS assess the DSM-
IV symptoms of ADHD in children and adolescents. The
inattentive and hyperactive-impulsive symptoms included
are: (1) inability to pay attention to details; (2) difficulty with
sustained attention in tasks or play activities; (3) listening
problems; (4) difficulty following instructions; (5) problems
organizing tasks and activities; (6) avoidance or dislike of tasks
that require mental effort; (7) tendency to lose things like toys,
notebooks, or homework; (8) distractibility; (9) forgetfulness in
daily activities; (10) fidgeting or squirming; (11) difficulty
remaining seated; (12) restlessness; (13) difficulty playing
quietly; (14) always seeming to be ‘‘on the go;’’ (15) excessive
talking; (16) blurting out answers before hearing the full
question; (17) difficulty waiting for a turn or in line; (18)
problems with interrupting or intruding. Three quantitative
measures were generated using both the CPRS-R:L and PACS,
resulting in a total of six quantitative measures to be used in
GWAS analyses. In the PACS, each symptom is given a value of
0 or 1 to demarcate the absence or presence of the symptom
respectively. Three basic measure that were generated using
data from the PACS, including a count of (1) the number
of exhibited hyperactive-impulsive symptoms; (2) the number
of exhibited inattentive symptoms; and (3) the total number of
exhibited ADHD symptoms. In all three cases, a binary
measure indicating the presence or absence of each symptom
was measured and the totals were generated by summing over
all symptoms, making the maximum number of symptoms 9, 9,
and 18 respectively. In the CPRS-R:L each symptom is given a
score ranging between 0 and 3, where 0 indicates that the
behavior is not characteristic of the individual and exhibited
rarely and 3 indicated that the behavior is very characteristic
of the individual and is exhibited very frequently. The three
remaining phenotypes were generated using data from the
CPRS-R:L with the Family-based association testing-principal
components (FBAT–PC) methodology [Lange et al., 2004b].
Because this approach has been presented and implemented
elsewhere [Van Steen et al., 2005; Herbert et al., 2006; Lasky-
Su et al., 2007, 2008], we do not provide the details here. In
summary, FBAT–PC uses a weighted sum of the inputted
phenotypes to construct a composite phenotype that is then
used in the association analysis. The weights for the composite
phenotype are generated to maximize the heritability at each
SNP while remaining statistically independent of any subse-
quent association tests. By maximizing the heritability at each
SNP we mean that the genotypic information is maximally
correlated with the composite phenotype. Because we are using
the between information on an SNP-by-SNP level, the
composite generated is different for each SNP/phenotype
combination. In this application, we use FBAT–PC with three
different sets of inputted variables to generate three separate
quantitative traits to be used in the association analyses:
ordinal measures of (1) the 9 inattentive symptoms; (2) the 9
hyperactive-impulsive symptoms; and (3) the total number of
ADHD symptoms. In total six phenotypes were analyzed using
additive, dominant, and recessive models. Considering that
there are six phenotypes and three genetic models, 18 GWAS
analyses were performed. When presenting the findings, the
results only adjust for multiple comparisons for a single GWAS
analysis (i.e., we adjust only for the statistical tests within the
specified phenotype and genetic model). We do not adjust for
the comparisons across all 18 GWAS analyses and acknowl-
edge that by doing this none of these findings achieve genome-
wide significance on an experiment-wise level. Therefore,
when we claim ‘‘significance’’ we are referring to any statistical
test that has a P-value less than 0.05 after adjusting for the
statistical tests performed for a single GWAS analysis. The
Spearman rank correlation between the total symptom count
and inattentive and hyperactive-impulsive symptom counts
was 0.78 and 0.73, respectively, while the correlation between
inattentive and hyperactive-impulsive symptom counts was
0.20. Because the FBAT–PC methodology generates a differ-
ent weighting scheme for each phenotype/SNP combination,
the correlation among the composite phenotypes is more
difficult to assess.
Genotyping
Details of the genotyping and data cleaning process were
reported elsewhere [Neale et al., 2008a]. Briefly, genotyping
was performed by Perlegen Sciences using the Perlegen
platform. The Perlegen Array has 600,000 tagging SNPs
designed to be in high linkage disequilibrium with untyped
SNPs for the three HapMap populations. Genotype data
cleaning and quality control procedures were done by The
National Center for Biotechnology Information (NCBI) using
the GAIN QA/QC Software Package (version 0.7.4) developed
by Gonc¸alo Abecasis and Shyam Gopalakrishnan at the
University of Michigan. A copy of the software is available by
e-mailing gopalakr@umich.edu or goncalo@umich.edu. Data
were removed on the basis of the following quality control
metrics: (1) call rate <95%; (2) gender discrepancy; (3) per-
family Mendelian errors >2; (4) sample heterozygosity <32%;
(5) genotype call quality score cut-off<10; (6) a combination of
SNP call rate and minor allele frequency (MAF) (a)
0.01MAF< 0.05 and call rate 99%; (b) 0.05MAF< 0.10
and call rate97%; and (c) 0.10MAF and call rate95%); (7)
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Hardy–Weinberg equilibrium P-value of P-value< 0.000001;
and 8) duplicate sample discordance. We also examined the QQ
plots for all of the phenotype and genetic model combinations to
insure that our results did not have more than expected low-P-
values. The process was also done with ADHD diagnosis in the
cleaning of these data.
Statistical Analyses
FBAT is a generalization of the TDT, which allows valid
testing of association with any phenotype, sampling structure,
and pattern of missing marker allele information [Horvath
et al., 2001, 2004; Lange et al., 2004a]. The PBAT program
incorporates the FBAT–PC methodology. We analyzed our
data using the FBAT–PC methodology in the context of the
PBAT screening algorithm. By using information from families
that are not informative for a given SNP (a.k.a. the between
information), PBAT selects a set of SNPs with the most power
to detect association in a manner that does not bias the
statistical test of association in the informative families [Lange
et al., 2003a,b]. This reduces the number of independent
comparisons by restricting the analysis to an abridged set of
SNPs. Simulations show that the PBAT screening procedure
has increased power over other multiple testing strategies such
as the Bonferroni correction [Van Steen et al., 2005]. One
criticism of the screening algorithm is that it uses the between
family information which can be affected by extreme popula-
tion stratification [Ionita-Laza et al., 2007]. We have pre-
viously shown that IMAGE participants from Israel and Spain
show different genetic profiles than the Northern European
participants [Neale et al., 2008b]. Combining all of these
individuals together results in a heterogeneous sample and
although the FBAT statistic is robust against population
stratification, the PBAT screening algorithm has some sensi-
tivity towards it. Therefore we performed a cluster analysis in
PLINK [Purcell et al., 2007] through a linkage clustering
algorithm that is based on pairwise identity-by-state distance,
to identify a predominant homogeneous cluster in our sample.
Information from this cluster was used to rank-order the SNPs
using the PBAT screening algorithm. It is important to note
that the subset of individuals was used in the PBAT screening
algorithm only. Because the FBAT statistic is robust to
population stratification, the entire sample may validly be
used in following statistical tests. Using the PBAT screening
algorithm we only formally test the top 10 ranked SNPs, and
therefore genome-wide significance can be established using a
much more liberal threshold than the 108 that has been
suggested for formal testing of all SNPs [Dudbridge and
Gusnanto, 2008]. In all analyses, we considered additive,
dominant, and recessive genetic models. Depending on the
genetic model, up to 35,000 additional SNPs had less than 20
informative families and were therefore not used in the
analysis. We also examined the association P-values of the
SNPs in a set of pre-specified ADHD autosomal candidate
genes that was generated by the IMAGE study investigators.
These genes are as follows: ADRA1A, ADRA1B, ADRA2A,
ADRA2C, ADRB1, ADRB2, ADRBK1, ADRBK2, ARRB1,
ARRB2, BDNF, CHRNA4, COMT, CSNK1E, DBH, DDC,
DRD1, DRD2, DRD3, DRD4, FADS1, FADS2, HES1, HTR1B,
HTR1E, HTR2A, HTR3B, NFIL3, NR4A2, PER1, PER2,
PNMT, SLC18A2, SLC6A1, SLC6A2, SLC6A3 (DAT1),
SLC6A4, SLC9A9, SNAP25, STX1A, STY1, TPH1, and
TPH2. Unfortunately there were no SNPs genotyped in
DRD5. Finally, we assessed the overlap between the associa-
tion findings in this manuscript and the findings in the initial
manuscript [Neale et al., 2008a] by looking at the SNPs with P-
values less than 0.0001 in the initial article and P-values less
than 0.05 in these analyses.
RESULTS
After the quality control procedures, 438,784 markers were
available for analytic use. The PBAT/FBAT programs are not
compatible with sex-linked markers. Consequently, we
restricted our statistical analysis to 429,981 autosomal
markers. A total of 2,803 individuals, 1,865 founders and 938
non-founders were included after the cleaning process. Of
these individuals, 29 offspring did not have clinical data and/or
parental genotypes resulting in 909 individuals used in the
analysis. A summary of the sample is listed in Table I. An
example QQ plot is given in Figure 1 and shows no notable
deviation from what would be expected under the null
hypothesis. Similar plots were found for all of the analyzed
phenotypes.
Using PLINK a homogeneous cluster of 1,409 founders,
including 660 families with both parents was identified. This
cluster was predominantly, but not exclusively made of
Northern Europeans. We used these 660 families in the PBAT
screening algorithm from which the P-values of the top 10
ranked SNPs for each phenotype and genetic model combina-
tion were identified and the FBAT statistic was evaluated in
the full sample. Two SNPs achieved significance within the
TABLE I. Descriptive Statistics of the Individuals Used in the
GWAS Analyses
Number of parents 1865
Number of children 938
Number of ADHD diagnosed children 933
Gender distribution of the offspring
Male (percent) 816 (86.99)
Female (percent) 122 (13.01)
Age among offspring (standard deviation) 10.88 (2.81)
Age at onset (standard deviation)
Inattention 4.31 (1.96)
Hyperactive-impulsive 2.77 (1.85)
Average number of inattentive symptoms 7.98 (1.37)
Average number of hyperactive-impulsive symptoms 8.11 (1.10)
Average total number of symptoms 16.10 (1.92)
Fig. 1. This is an example QQ plot of the cleaned GWAS data using
FBAT-PC with all symptoms using the recessive model. This figure shows
that there is no deviation from what would be expected by chance.
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specified GWAS analysis. We did not adjust for the tests from
all 18 GWAS analyses, but we only adjusted for the SNPs
selected from the PBAT screening algorithm for the phenotype
and genetic model that was used. If we adjust for selected SNPs
from all 18 GWAS analyses, these SNPs do not achieve
significance. Rs6565113 was significant for the FBAT–PC
phenotype using all symptoms and an additive model while
rs552655 was significant with the FBAT–PC using inattentive
symptoms and a dominant model. Additional details include
the minor allele frequency of the SNP, the number of
informative families, the P-value, and the power ranking is
listed in Table II. Rs6565113 is located in an intronic region of
CDH13. Figure 2 illustrates the association P-values for all
SNPs in CDH13 under the same model and phenotype as the
significant effect. Correlations between the FBAT–PC compo-
site phenotype and the 18 individual ADHD symptoms show
that rs6565113 is most strongly associated with ‘‘excessive
talking’’ and ‘‘difficulty with sustaining attention’’ whereas
rs552655 is more strongly associated with ‘‘loses things’’ and
‘‘difficulty with sustaining attention.’’
Among all 18 GWAS analyses, there were 58 association
tests with 46 unique SNPs that had a P-value <105. The
association analyses identified two SNPs in IL16, two SNPs in
LOC390980, and one SNP in or proximal to each of the
following genes: CLYBL, FHIT, FOXP1, HAS3, LPL, MEIS2,
NAPRT1, OXER1, DMTR2, GRIK1, SLCO3A1, ZNF423, and
ZNF544. A summary of these findings can be found in Table III,
which lists the associated SNP with other relevant information
including the genetic model, the number of informative
families, the P-value, the location, and any flanking genes
within 10 kb from the SNP. Flanking genes are provided to
consider the potential LD between the SNP and nearby genes.
There were numerous associations at the candidate gene
SNPs with a P-value <0.01. Table IV lists the number of
significant SNPs for each candidate genes, the number of
different haplotypes these SNPs represent using the criteria by
Gabriel et al. [2002], and the lowest association P-value at each
candidate gene by phenotype. SLC9A9 had 53 nominally
significant P-values that were less than 0.01 and three
association P-values with a magnitude of 105 in two distinct
regions of the gene. RS1001478 is in an intronic region that had
P-values of 3.89 105 and 1.85 105 for FBAT–PC with all
symptoms and hyperactive-impulsive symptoms respectively
while RS1992426 is downstream of SLC9A9 and had a P-value
of 5.96 105 using FBAT–PC with inattentive symptoms.
Furthermore RS1875460, RS9819943, RS10513201, RS1875460,
and RS1978913 had association P-values with a magnitude of
103 or less. Figure 3 illustrates the association findings in
SLC9A9 using FBAT–PC with the hyperactive-impulsive
phenotype. Nominally significant SNPs in SLC9A9 were found
over a broad portion of the gene, covering seven distinct
haplotypic regions. Because the number of SNPs and the
linkage disequilibrium patterns vary for each candidate gene,
this information must be considered in assessing the overall
evidence for association at each candidate gene. Genes
SLC9A9, ADRAIA, HTR2A, SNAP25, and SLC6A2 had the
largest number of SNPs with 181, 47, 40, 28, and 27
respectively whereas ADRA2A, ADRBK1, ADRBK2, DRD4,
HES1, and PNMT only had one SNP each. Given the haplotype
block structures for these genes, the nominal findings
represent anywhere between 1 and 7 distinct regions.
Table V summarizes the overlap of these findings with the
initial manuscript [Neale et al., 2008a] by listing SNPs that
had a P-value<0.0001 in the initial article and a P-value<0.05
in any of the analyses presented here. Annotation data for
these 25 SNPs, including chromosomal location, possible
functionality, and nearby genes, were found using SCAN
(http://genemem.bsd.uchicago.edu/newscan/). In addition,
Table V lists the overlap between these results and previous
genetic findings for other psychiatric disorders (https://
slep.unc.edu/evidence/).
DISCUSSION
In this analysis we used six quantitative phenotypes, derived
from the 18 DSM-IV ADHD symptoms, and three genetic
models to perform 18 GWAS analyses with 909 trios (660 trios
were used in the screening algorithm, but the full sample was
used in the actual analysis). No SNPs achieved genome-wide
significance after adjusting for multiple comparisons among all
GWAS analyses. By using the PBAT screening algorithm to
select the 10 highest-powered SNPs per phenotype/genetic
model combination, 2 SNPs did achieve significance within a
single GWAS analysis.
TABLE II. A Summary of the SNPs That were Significant Within a Phenotype Using the PBAT Screening Algorithm with Various
Quantitative Phenotypes
SNP Phenotype
Genetic
model
Minor allele
frequency
Number of
informative
families P-value
Power
ranking
Gene,
location
rs6565113 FBAT–PC with all
symptoms
Additive 0.470 656 0.005 1 Intron in
CDH13
rs552655 FBAT–PC with
inattentive symptoms
Dominant 0.468 489 0.004 2 Intron in
GFOD1
Fig. 2. This figure represents the negative log P-values for SNPs in
SLC9A9 using the FBAT-PC methodology with inattentive symptoms using
the additive model.
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Using the PBAT screening algorithm, we found two SNPs
that were significant within the GWAS analysis for the
specified phenotype and genetic model. Rs6565113, an intronic
SNP in Cadherin 13 (CDH13), achieved significance within the
FBAT–PC phenotype including all ADHD symptoms. CDH13
acts as a negative regulator of neural cell growth [Takeuchi
et al., 2000] and is expressed in brain regions that structural
imaging has also shown to have volumetric reductions in
ADHD-diagnosed individuals [Takeuchi et al., 2000; Valera
et al., 2007]. The SNP is located in the region where a linkage
peak was identified with the IMAGE data using an affection
status phenotype [Asherson et al., 2008]. In addition, a recent
TABLE III. A Summary of the Association Findings With P-Values Less Than 105 Using the Various Phenotypes
Phenotype SNP
Genetic
model
Number of
informative
families P-value Chr Base pairs Flanking gene/function
FBAT–PC all rs1018040 Additive 363 4.64E06 1 216772437
symptoms rs1018040 Dominant 351 2.97E06 1 216772437
rs930421 Recessive 261 5.64E06 2 42834743 OXER1, downstream
rs7577925 Dominant 499 2.55E06 2 133756989 FLJ34870, intron
rs1350666 Additive 571 8.30E06 4 75443454 EREG, promoter
rs708188 Recessive 176 7.21E06 12 28111983
rs522958 Recessive 265 1.03E06 12 28119834
rs1514928 Additive 261 3.05E06 14 61748056
rs8047014 Additive 648 3.52E06 16 67692550 HAS3, promoter
rs260461 Dominant 376 8.38E06 19 63462695 ZNF544, intron
rs130575 Additive 389 4.67E06 22 33189793
rs130575 Dominant 376 6.20E06 22 33189793
FBAT–PC rs1018040 Additive 363 8.20E06 1 216772437
hyperactive- rs6719977 Additive 663 1.67E06 2 42839307 OXER1,downstream
impulsive
symptoms
rs6808138 Additive 379 5.38E06 3 162875270
rs6808138 Dominant 373 8.21E06 3 162875270
rs17641078 Additive 322 4.73E06 9 1046959 DMRT2, coding exon
rs17641078 Dominant 315 8.44E06 9 1046959 DMRT2, coding exon
rs708188 Recessive 176 2.17E06 12 28111983
rs522958 Recessive 265 7.59E07 12 28119834
rs363512 Dominant 209 3.89E06 21 29972688 GRIK1, intron
rs41441749 Dominant 470 1.49E06 6 18899702
FBAT–PC rs4147141 Additive 383 7.90E06 1 69351840
inattentive rs4650135 Additive 595 5.45E06 1 69457585
symptoms rs4650135 Dominant 254 6.07E06 1 69457585
rs11786458 Additive 272 8.76E06 8 40371858
rs12679254 Recessive 327 2.08E06 8 74436745
rs11790994 Additive 233 2.47E07 9 97469087
rs10895959 Recessive 232 3.00E06 11 105835372
rs17079773 Additive 361 4.71E06 13 23496384
rs17079773 Dominant 263 6.60E06 13 23496384
rs7495052 Recessive 327 2.83E06 15 90353033 SLCO3A1, intron
rs17281813 Recessive 672 3.46E06 16 48308291 ZNF423, intron
rs13330107 Recessive 327 8.50E06 16 75436363
rs478597 Additive 502 8.08E06 12 116235808
Total ADHD rs272000 Recessive 311 9.10E06 2 116372265
symptom rs17367118 Additive 269 8.69E06 2 123358081
count rs1918172 Additive 36 5.18E06 2 156596746
rs11719664 Additive 183 2.48E06 3 21930202
rs6791644 Recessive 254 8.32E06 3 60746148 FHIT, intron
rs17651978 Recessive 449 6.05E06 3 71103180 FOXP1, intron
rs2290416 Additive 549 8.51E06 8 144728743 NAPRT1, coding exon
rs10767942 Dominant 383 7.90E06 11 32478583
rs7992643 Dominant 595 5.45E06 13 99353039 CLYBL, intron
rs4147141 Additive 254 6.07E06 1 69351840
Hyperactive- rs11590090 Recessive 208 2.51E06 1 113115086
impulsive rs1202199 Dominant 291 8.52E06 6 20264153
symptom rs7816032 Recessive 139 2.25E06 8 19831171 LPL, promoter
count rs8041675 Additive 695 3.98E06 15 35129894 MEIS2, intron
rs13353224 Additive 222 8.54E06 16 63551405
rs2014572 Additive 676 7.32E06 19 62451830 LOC390980, promoter
rs10421632 Additive 694 9.68E06 19 62456582 LOC390980, promoter
Inattentive rs10227331 Recessive 415 3.79E06 7 156987699
symptom rs2769967 Recessive 404 3.63E06 9 81079178
count rs1471225 Additive 669 8.09E06 15 27675688
rs7172689 Additive 512 3.86E06 15 79320750 IL16, intron
rs7172689 Dominant 478 1.50E06 15 79320750 IL16, intron
rs4128767 Dominant 545 1.28E06 15 79330462 IL16, intron
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GWAS analysis found and replicated the association of several
SNPs in CDH13 (OMIM¼ 601364) with methamphetamine
dependence [Uhl et al., 2008]. A common comorbidity of ADHD
is substance abuse/dependence, which makes this gene a
viable candidate for ADHD as well. Clearly, future replication
efforts are required to either verify or refute this gene as a
genetic variant for ADHD. Rs552655 achieved significance
with the FBAT–PC phenotype for inattentive symptoms. Al-
though this is not an obvious biologic candidate, rs552655 is
located in GFOD1 (UGID:699845), encoding glucose-fructose
oxidoreductase domain containing 1, a protein predicted to be
involved in electron transport and metabolic processes (e.g.,
Entrez Gene, URL: http://www.ncbi.nlm.nih.gov/sites/entrez?
Db¼gene&Cmd¼ShowDetailView&TermToSearch¼ 54438
&ordinalpos¼3&itool¼EntrezSystem2.PEntrez.Gene.Gene_
ResultsPanel.Gene_RVDocSum’). Although there is no overlap
between this finding and previous ADHD studies, a meta-
analysis of genome-wide linkage studies found two markers
near GFOD1 that were associated withschizophrenia (D6s274–
D6S1586 with a P-value of 0.033 and 6PTER–D6S274 with a
P-value of 0.016) [Lerer et al., 2003].
We identified 58 statistical tests with 46 unique SNPs that
had uncorrected association signals at P-values <105.
Although none of the genes in Table III have been identified
as good candidate genes for ADHD, GRIK1, and SLCO3A1
have been implicated as potential candidates for other
psychiatric disorders. Genes involved in glutamatergic trans-
mission, including GRIK1 (a.k.a. GluR5 kainate receptor
gene), have been suggested as candidate genes for schizophre-
nia and mood disorders [Shibata et al., 2001]. Decreased
expression of GRIK1 was detected in the perirhinal cortex for
major depressive disorder, bipolar disorder, and schizophre-
nia, suggesting that this may be an important factor in the
etiology of these psychiatric disorders [Beneyto et al., 2007].
Additional evidence suggests that SLCO3A1 may be associated
with schizophrenia. A whole genome scan was performed using
a measure of QT prolongation that was drug induced in
schizophrenic patients. This study identified DNA polymor-
phisms in SLCo3A1 associated with QT prolongation in
schizophrenic patients [Volpi et al., 2008]. Another study
found nominal significance with SLCO3A1 in early-onset
major depressive disorder [Verma et al., 2008]. There is some
overlap between these GWAS findings and previous ADHD
linkage results. The association finding in the promoter region
of EREG, rs1350666, is proximal to the linkage region
identified by Arcos-Burgos et al. [2004]. rs7992643, a SNP in
an intronic region of CLYBL is also proximal to a peak LOD
score identified in another ADHD linkage study [Bakker et al.,
2003]. This finding also had overlap with linkage peaks for
schizophrenia [Blouin et al., 1998] and bipolar disorder
[Detera-Wadleigh et al., 1999]. rs8041675 is in an intronic
region of MEIS2 and is proximal to an ADHD linkage finding at
D15S194 [Bakker et al., 2003]. There was also overlap between
the 18 GWAS analyses and linkage results from other
psychiatric disorders. rs7577925 was found to be proximal to
TABLE IV. The Lowest Association P-Value for each Phenotype Identified From the SNPs Within Each ADHD Candidate Gene
Candidate gene SNPs
Number of
haplotype
blocks
P-value of most strongly associated SNP for each candidate gene*
FBAT–PC Symptom count
All H-I I All H-I I
SLC6A1 4 2 0.0013 0.0041
SLC9A9 32 7 3.89 105 1.85105 5.96105 0.0013 2.38104 0.0078
ADRB2 1 1 0.0051
HTR1E 1 1 0.0053
DDC 4 1 0.0055 5.3 104
ADRA1A 6 3 0.0023 0.0016 0.0092 0.0050
DBH 5 1 0.0089 0.0017 0.0059 0.0054 0.0057
BDNF 2 2 0.0051 0.0004
DRD2 1 1 0.0051 0.0013
TPH2 4 1 0.0084 0.0051 0.0023
HTR2A 3 3 0.0046 0.0088 0.0046
SLC6A2 1 1 0.0009
PER1 1 1 0.0055
CHRNA4 1 1 0.0019
SNAP25 6 2 0.0036 4.84 104 0.0012 0.0045
COMT 1 1 0.0044
SYT1 1 1 0.0026
All, all ADHD symptoms; HI, hyperactive-impulsive symptoms; I, inattentive symptoms.
*P-values are only presented for a gene is the at least one SNP in the gene had a P-value <0.01.
Fig. 3. This figure represents the negative log P-values for SNPs in
SLC9A9 using the FBAT-PC methodology with all ADHD symptoms using
the recessive model.
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a schizophrenia linkage peak [Moises et al., 1995] and
rs363512 is in the same region as rs2154490, which was
nominally associated with bipolar disorder in a recent GWAS
analysis (Anon., 2007). Although many of these associations
are with other psychiatric disorders, the comorbidity among
these conditions suggests that these genes may be more
promising to follow-up in replication.
There were many positive associations with specified ADHD
candidate genes. Among the candidate genes, the strongest
evidence for association was for SLC9A9, which codes for a
sodium/hydrogen exchanger that is expressed in the brain.
Nominally significant SNPs in SLC9A9 were found over a
broad portion of the gene, covering seven distinct haplotypic
regions. This suggests that there may be more than one genetic
signal in this gene, however replication of the findings is
necessary before anything can be concluded. SLC9A9, which is
located on chromosome 3q24, has been suggested as a strong
candidate for ADHD because it is located at a translocation
breakpoint in a family having multiple cases of ADHD [de Silva
et al., 2003].
The overlap between the findings in this article and the
initial association analysis with these data provide a list of
SNPs that are consistently nominally significant among at
least two ADHD phenotypes. This robustness suggests that
these SNPs are good candidate to take forward to replication.
In addition, a large portion of these SNPs are located in regions
where there have been previous reports for significant findings
of various psychiatric diseases including ADHD, schizophrenia,
TABLE V. The SNPs That Have a P-value<0.0001 in the Neale et al. [2008a] Article and a P-Value<0.05 in any of the GWAS Analyses
Presented in this Article
Rs number Chr Position Alleles Gene Function
Gene to the
left
Gene to the
right
Previous findings
with other
psychiatric disorders
rs4241112 2 122378682 CT TSN AX747402
rs349158 3 62054285 CT PTPRG intron FHIT AK094634 BP [2007]
rs17689952 4 167158604 AG TLL1 intron CPE SPOCK3
rs12505502 4 91787046 GT MGC48628 intron MMRN1 TMSL3 BP [2007]
rs13120644 4 56293259 CG NMU EXOC1
rs876477 4 20766026 CT KCNIP4 intron C4orf28 BC014938 ND [Li et al., 2008]
rs1541665 5 170075495 CT KCNIP1 intron KCNMB1 GABRP SCZ [Lewis et al.,
2003]
rs17673653 5 170099172 AT KCNIP1 GABRP
rs1062793 6 80468115 AG SH3BGRL2 mrna-utr BX648161 ELOVL4 ADHD [Ogdie et al.,
2003]
rs13215768 6 4618712 AG KU-MEL-3 CDYL
rs3734552 6 137154326 AG MAP3K5 intron MAP7 PEX7 SCZ [Lerer et al.,
2003]
rs6570426 6 141239039 AT BC038188 AK097143
rs6919857 6 137182147 CT MAP3K5 PEX7
rs9389835 6 141312353 CT BC038188 AK097143
rs964647 6 88993111 AT CNR1 RNGTT
rs703965 10 80625073 CT ZMIZ1 intron AK098249 PPIF SCZ [Fallin et al.,
2003; Faraone
et al., 2006]
rs11221064 11 127192523 CG BC030092 ETS1
rs17754282 11 87622650 GT RAB38 CTSC
rs3782309 12 26750663 GT ITPR2 intron SSPN C12orf11
rs17722514 13 89511946 CT SLITRK5 BC038529
rs922781 15 58857636 CG RORA intron BC035094 BC033962
rs4149601 18 53967789 AG NEDD4L intron AK056031 CR596491 SCZ/BP [Maziade
et al., 2005]
rs9676447 19 54116059 CT NUCB1 intron TULP2 DHDH
rs957794 21 45583194 CG AK056166 COL18A1
rs957795 21 45583147 AG AK056166 COL18A1
BP, Bipolar Disorder; SCZ, Schizophrenia; ND, Nicotine Dependence.
Fig. 4. This figure represents the negative log P-values for SNPs in
CDH13 using the FBAT-PC methodology with all ADHD symptoms using
the additive model.
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nicotine dependence, and bipolar disorder. rs1062793 is
actually in a region that was previously reported to have some
level of association with ADHD itself [Ogdie et al., 2003].
Despite not finding genome-wide significant associations of
SNPs with the quantitative ADHD phenotypes after adjusting
for all 18 GWAS analyses, the results presented in this article
should be considered a valuable dataset for replication in
independent populations. Using ADHD symptoms, as the
quantitative trait should greatly facilitate replication efforts
compared to other quantitative traits, as these measures are
commonly used and likely to be included in other datasets.
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